BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22629454)

  • 1. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.
    Lockwood WW; Wilson IM; Coe BP; Chari R; Pikor LA; Thu KL; Solis LM; Nunez MI; Behrens C; Yee J; English J; Murray N; Tsao MS; Minna JD; Gazdar AF; Wistuba II; MacAulay CE; Lam S; Lam WL
    PLoS One; 2012; 7(5):e37775. PubMed ID: 22629454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Copy Number Signatures Uncovered a Genetically Distinct Group from Adenocarcinoma and Squamous Cell Carcinoma in Non-Small Cell Lung Cancer.
    Lee E; Moon JW; Wang X; Kim C; Li S; Shin BK; Jung W; Kim HK; Kim HK; Lee JY
    Hum Pathol; 2015 Aug; 46(8):1111-20. PubMed ID: 26003479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.
    Lockwood WW; Chari R; Coe BP; Thu KL; Garnis C; Malloff CA; Campbell J; Williams AC; Hwang D; Zhu CQ; Buys TP; Yee J; English JC; Macaulay C; Tsao MS; Gazdar AF; Minna JD; Lam S; Lam WL
    PLoS Med; 2010 Jul; 7(7):e1000315. PubMed ID: 20668658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alterations defining NSCLC subtypes and their therapeutic implications.
    Pikor LA; Ramnarine VR; Lam S; Lam WL
    Lung Cancer; 2013 Nov; 82(2):179-89. PubMed ID: 24011633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma.
    Staaf J; Isaksson S; Karlsson A; Jönsson M; Johansson L; Jönsson P; Botling J; Micke P; Baldetorp B; Planck M
    Int J Cancer; 2013 May; 132(9):2020-31. PubMed ID: 23023297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.
    Nishino M; Hoang MP; Della Pelle P; Morales-Oyarvide V; Huynh TG; Mark EJ; Mino-Kenudson M
    Cancer Cytopathol; 2016 Jul; 124(7):472-84. PubMed ID: 27412420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized therapy on the horizon for squamous cell carcinoma of the lung.
    Kim HS; Mitsudomi T; Soo RA; Cho BC
    Lung Cancer; 2013 Jun; 80(3):249-55. PubMed ID: 23489560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex analysis of the p53 tumor suppressor in lung carcinoma.
    Smardova J; Liskova K; Ravcukova B; Malcikova J; Hausnerova J; Svitakova M; Hrabalkova R; Zlamalikova L; Stano-Kozubik K; Blahakova I; Speldova J; Jarkovsky J; Smarda J
    Oncol Rep; 2016 Mar; 35(3):1859-67. PubMed ID: 26718964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classification of non-small cell lung cancer based on copy number alterations.
    Li BQ; You J; Huang T; Cai YD
    PLoS One; 2014; 9(2):e88300. PubMed ID: 24505469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
    Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
    J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome analyses identify the genetic modification of lung cancer subtypes.
    Zhang Y; Wang DC; Shi L; Zhu B; Min Z; Jin J
    Semin Cancer Biol; 2017 Feb; 42():20-30. PubMed ID: 27845189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
    J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplatform-based molecular subtypes of non-small-cell lung cancer.
    Chen F; Zhang Y; Parra E; Rodriguez J; Behrens C; Akbani R; Lu Y; Kurie JM; Gibbons DL; Mills GB; Wistuba II; Creighton CJ
    Oncogene; 2017 Mar; 36(10):1384-1393. PubMed ID: 27775076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common and contrasting genomic profiles among the major human lung cancer subtypes.
    Tonon G; Brennan C; Protopopov A; Maulik G; Feng B; Zhang Y; Khatry DB; You MJ; Aguirre AJ; Martin ES; Yang Z; Ji H; Chin L; Wong KK; Depinho RA
    Cold Spring Harb Symp Quant Biol; 2005; 70():11-24. PubMed ID: 16869734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach.
    Bishop JA; Benjamin H; Cholakh H; Chajut A; Clark DP; Westra WH
    Clin Cancer Res; 2010 Jan; 16(2):610-9. PubMed ID: 20068099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
    Sigel CS; Moreira AL; Travis WD; Zakowski MF; Thornton RH; Riely GJ; Rekhtman N
    J Thorac Oncol; 2011 Nov; 6(11):1849-56. PubMed ID: 21841504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
    Goodwin J; Neugent ML; Lee SY; Choe JH; Choi H; Jenkins DMR; Ruthenborg RJ; Robinson MW; Jeong JY; Wake M; Abe H; Takeda N; Endo H; Inoue M; Xuan Z; Yoo H; Chen M; Ahn JM; Minna JD; Helke KL; Singh PK; Shackelford DB; Kim JW
    Nat Commun; 2017 May; 8():15503. PubMed ID: 28548087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma.
    Qin N; Li Y; Wang C; Zhu M; Dai J; Hong T; Albanes D; Lam S; Tardon A; Chen C; Goodman G; Bojesen SE; Landi MT; Johansson M; Risch A; Wichmann HE; Bickeboller H; Rennert G; Arnold S; Brennan P; Field JK; Shete S; Le Marchand L; Melander O; Brunnstrom H; Liu G; Hung RJ; Andrew A; Kiemeney LA; Zienolddiny S; Grankvist K; Johansson M; Caporaso N; Woll P; Lazarus P; Schabath MB; Aldrich MC; Stevens VL; Jin G; Christiani DC; Hu Z; Amos CI; Ma H; Shen H
    Front Med; 2021 Apr; 15(2):275-291. PubMed ID: 32889700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.